NCT07616700RecruitingPhase 2
A Multicenter, Open-Label Phase II Clinical Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in the Treatment of Primary IgA Nephropathy
Haisco Pharmaceutical Group Co., Ltd.2 sites in 1 country73 target enrollmentStarted: August 25, 2025Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 73
- Locations
- 2
Study Overview
Brief Summary
This is a Phase II, multicenter, open-label study. Eligible subjects who have completed the HSK39297-202 study will be enrolled.Starting dose is 200 mg QD.Dose may be increased to 300 mg QD after 8-12 weeks of stable 200 mg QD therapy if 24-h urine protein excretion (UPE) remains >1 g/24 h and no Grade ≥3 treatment-related adverse events (AEs) occur.After the treatment period, subjects will enter the 4-week safety follow-up period.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Completed the HSK39297-202 study and assessed by the investigator to have a favorable benefit-risk profile for 200 mg QD HSK
- •eGFR ≥30 mL/min/1.73 m² at screening (calculated by CKD-EPI 2021 equation).
- •Able to maintain optimized, stable background therapy with RAS blockers, SGLT2 inhibitors, endothelin receptor antagonists, or hydroxychloroquine during the study.
- •Vaccinated against Neisseria meningitidis and Streptococcus pneumoniae as required in the previous study (booster if needed).
- •Fertile females: negative serum pregnancy test; highly effective contraception from signing informed consent until 30 days after last dose.
- •Fertile males: highly effective contraception from signing informed consent until 90 days after last dose.
- •Voluntarily provided written informed consent and able to comply with study procedures
Exclusion Criteria
- •Known or suspected hereditary or acquired complement deficiency.
- •Active primary or secondary immunodeficiency.
- •History of bone marrow / hematopoietic stem cell or solid organ transplantation.
- •Malignancy within the past 5 years (except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix).
- •History of recurrent invasive infections caused by encapsulated bacteria (e.g., N. meningitidis, S. pneumoniae) or Mycobacterium tuberculosis.
- •Severe concomitant diseases judged by the investigator to be incompatible with study participation.
- •Suspected hypersensitivity to the investigational product or its class.
- •Pregnant or lactating females.
- •Other conditions that may interfere with the study or increase subject risk.
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Phase 3
A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis BronchiectasisNCT07616375Haisco Pharmaceutical Group Co., Ltd.669
Recruiting
Phase 2
A Study for HSK47388 in Participants With Ulcerative ColitisNCT07335055Haisco Pharmaceutical Group Co., Ltd.150
Recruiting
Phase 2
Phase II Clinical Study of the Efficacy and Safety of HSK55718 in the Treatment of Abdominal Postoperative PainPain After Abdominal SurgeryNCT07491146Yingyong Zhou,MD,PhD200
Not yet recruiting
Phase 2
Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell LymphomasNCT07387848American University of Beirut Medical Center40
Not yet recruiting
Phase 3
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerNCT07441460Shanghai JMT-Bio Inc.1,800